New #Stocks to Watch at Investor Ideas in Biotech (NasdaqGS: $IPSC) (NYSE: $AMAM), (NasdaqGS: $CYT) and Cannabis (CSE: $POKO.C), (CSE: $RIV.C)

  New #Stocks to Watch at Investor Ideas in Biotech (NasdaqGS: $IPSC) (NYSE: $AMAM), (NasdaqGS: $CYT) and Cannabis (CSE: $POKO.C), (CSE: $RIV.C)

 

Also new stocks in Mining, Cleantech and Psychedelics

 

 

 

 

 

 

 

 

 

 

Point Roberts WA, Delta BC, August 27, 2021 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in biotech, cannabis, mining, cleantech and psychedelics. Today’s stocks have been added to our lists of free stock directories in each sector.

 

Read this in full at https://www.investorideas.com/news/2021/main/08271Stocks.asp

 

The newest biotechnology companies are involved in biotech, biopharma and biomedical along with life sciences and healthcare technology.

 

The latest cannabis companies include both a CBD and a cannabis focused company.

 

The newest mining companies are both Canadian-listed, as is the latest cleantech company.

 

The newest psychedelics company is involved in the use of ketamine-enhanced products for psychotherapy.

 

New Stocks added to Biotech Stocks Directory:

FEMASYS INC  (NasdaqCM:FEMY) is a biomedical company developing a suite of product candidates to transform women’s healthcare with minimally invasive, non-surgical, in-office technologies. Its two lead reproductive health product candidates include FemBloc® permanent birth control and FemaSeed™ localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound FemVue®, is currently marketed in the United States. Femasys is also advancing FemCerv®, a technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician’s office setting.

 

Codex DNA, Inc. (NasdaqGS:DNAY) is empowering scientists with the ability to address many of humanity’s greatest challenges through synthetic biology. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA is enabling rapid, accurate, and reproducible writing of DNA and mRNA for numerous downstream markets. The company’s award-winning BioXp™ system consolidates, automates, and optimizes the entire synthesis, cloning, and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA/RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm to create novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Codex DNA is a public company based in San Diego.

 

Alzamend Neuro, Inc. (NasdaqCM:ALZN) is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic crystal-engineered combination of lithium, proline and salicylate, and AL002 – a patented therapeutic mutant-peptide sensitized cell-based therapeutic vaccine that is targeted to augment the ability of a patient’s immune system to combat Alzheimer’s disease. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

 

MOLECULAR PARTNERS AG (NasdaqGS:MOLN) is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

 

Lyell Immunopharma, Inc. (NasdaqGS:LYEL) is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. The Company focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses to adoptive T cell therapy: T cell exhaustion and lack of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes. Lyell is based in South San Francisco, California and Seattle and Bothell, Washington.

 

Unicycive Therapeutics, Inc. (NasdaqCM:UNCY) is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

 

Cyteir Therapeutics, Inc. (NasdaqGS:CYT)         is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

 

Ambrx Biopharma Inc. (NYSE:AMAM) is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology.

 

Century Therapeutics, Inc. (NasdaqGS:IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care.

 

iSpecimen Inc. (NasdaqCM:ISPC) offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations.

 

SpotLite360 IOT Solutions, Inc. (CSE:LITE) is a supply chain and healthcare company focused on the delivery of a SaaS-based supply chain execution and sustainability platform (SpotLite 360 Software) for enterprise customers in the pharmaceutical, healthcare, and agricultural industries. By leveraging IoT technologies, blockchain, machine learning and analytics, the Spotlite360 Software is uniquely positioned to meet customer needs for supply chain execution, tracing, tracking, and sustainability. Future customers of the Spotlite360 Software will benefit by realizing improved visibility, a reduction in loss and theft, increased supply chain velocity, labor efficiency, improves asset utilization, and support of their global sustainability initiatives.

 

New stocks added to Cannabis Stocks Directory:

RIV Capital Inc. (CSE: RIV) is an investment and acquisition company specializing in cannabis with a portfolio of 13 companies across various segments of the cannabis value chain. We believe that bringing together people, capital, and ideas raises the potential of the entire cannabis industry. By leveraging our industry insights, in-house expertise, and thesis-driven approach to investing, we aim to provide shareholders with exposure to specialized and disruptive cannabis companies.

 

Poko Innovations Inc. (CSE: POKO) Formerly Brunswick Resources Inc.- is an award winning European-based company that leverages its strong portfolio of CBD brands, including financial services platform Lumipay, news and media sites, The Extract and Candid Magazine and consumer brands Poko and Canndid.  These brands form a complete ecosystem that brings innovative solutions to the CBD industry-from supplying businesses with high-quality CBD-derived products and other natural health supplements to offering a reliable payment gateway service for high-risk industries and providing a CBD-focused marketplace for buyers and sellers to connect and trade. The Company has leadership teams located in Ireland, United Kingdom, Canada and the United States.

 

New stocks added to Mining Stocks Directory:

1111 Exploration Corp. (CSE:ELVN) is a junior exploration company, focused on creating shareholder value through acquisition, exploration and development of mineral projects.

 

Fokus Mining Corporation (TSXV:FKM) is a mineral resource company actively acquiring and exploring precious metal deposits located in the province of Quebec, Canada. In implementing this major undertaking within the Canadian mining industry, we are determined to unlock the secret of the Galloway gold project. The Galloway project covers an area of 2,865.54 hectares and is located just north of the Cadillac-Larder Lake deformation which extends laterally for more than 100 km. Numerous gold deposits are related to that structure and its subsidiaries. The current work focuses on a small western portion of the mineral claims where several mineral occurrences have been identified

 

New stocks added to Cleantech Stocks Directory:

Delta Cleantech Inc. (CSE: DELT) provides clean energy engineering services and technology in response to issues around environmental, social and corporate governance (ESG) and identity preserved waste. Delta CleanTech is a technology industry leader in CO2 Capture; Solvent & Glycol Reclamation and Hydrogen Fueling Infrastructure         

 

New stocks added to Psychedelics Stocks Directory:

Revitalist Lifestyle and Wellness Ltd. (CSE:CALM) provides patient-focused treatments for mental health and pain disorders through the operation of psychedelic-enhanced psychotherapy clinics, which guide patients through ketamine-enhanced psychotherapy. Revivalist commenced operations in 2018 at is existing location in Knoxville Tennessee and is working on a rapid expansion in the United States. Revivalist seeks to create a global brand of psychedelic-enhanced psychotherapy clinics for ketamine-enhanced psychotherapy, psychedelic-enhanced psychotherapy, ketamine infusion therapy, vitamin infusions, and transcranial magnetic stimulation focusing on mental health and pain disorders

 

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

 

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors.  Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast ,  Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and  the AI Eye Podcast.

 

Learn about investing in stocks and sector trends with our news alerts, articles,  podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining and the AI Eye.

 

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.  

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android  

 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411